Cyclic Glycine-Proline vs HGH
Moderate Research vs FDA Approved
monitor Mechanism-based · 47% Both Cyclic Glycine-Proline and HGH affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Cyclic Glycine-Proline HGH
Weight 154.17 Da 22,124 Da
Half-life Extended stability (more stable than linear GPE precursor) 3-4 hours (SC), 20-30 minutes (IV)
Chain 2 amino acids (cyclic) 191 amino acids
Type Cyclic dipeptide (2,5-diketopiperazine) Single-chain polypeptide with two disulfide bridges
Key Benefits
Cyclic Glycine-Proline
01 Neuroprotection and cognitive enhancement
02 IGF-1 optimization
03 Cardiovascular support
04 Metabolic health improvement
05 Blood-brain barrier penetration
06 Convenient oral administration
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Cyclic Glycine-Proline
20-100 μg daily (or 300mg blackcurrant extract 2x daily) / Once daily, preferably in the morning
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Cyclic Glycine-Proline
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Consult healthcare provider if taking IGF-1 or growth hormone medications
Limited long-term human data available
Not studied in pregnancy
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Cyclic Glycine-Proline HGH
Status Moderate Research FDA Approved
References 4 studies 4 studies
Latest — 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.